CellRapeutics™ pan-ErbB-targeted Combination CAR-T Cell Engineering Service

The Potential of Targeting ErbB Family Cancer Therapy

CAR-T Immunotherapy has achieved unprecedented response rates in B-cell malignancies and myeloma patients. While the application of CAR-T therapy in solid tumors is not satisfactory. The lack of cancer-specific antigens, poor trafficking and penetration of CAR-T cells into malignant sites, and tumor microenvironment have led to this challenge. Currently, a wide range of target antigens are being studied for solid tumor therapy, and the ErbB family serves as a rich source of antigen candidates based on a variety of characteristics including prevalence, immunogenicity, and specificity.

Fig.1 TME hurdles in CAR-T Cell Immune Therapy for Solid Tumors.¹

Our CellRapeutics™ pan-ErbB-targeted Combination CAR-T cell Engineering Service

To address these issues, Creative Biolabs provides a robust and effective pan-ErbB-targeted combination CAR-T cell engineering service to speed up global customers' solid research. The pan-ErbB-targeted combination CAR-T strategy incorporates the promiscuous ErbB ligand T1E, placed upstream of a second-generation CAR design with a chimeric cytokine receptor (CCR). This approach could simultaneously direct T-cells specifically target all ErbB1 homo- and heterodimers, the ErbB 2/3 heterodimer, and all ErbB4 homo- and heterodimers expressing tumor cells with potent cytotoxic activity against a broad range of tumor types, decreasing the risk of immune evasion. Powered by our years of experience in the CAR-T field, we provide a one-stop pan-ErbB-targeted combination CAR-T cell engineering service, including from CAR design & construction, to function validation to speed up customers' solid research.

Fig.2 Schematic of pan-ErbB-targeted combination CAR-T cell engineering.

What We Can Offer

To execute highly complex pan-ERBB and armored CAR-T engineering, we leverage a suite of validated, high-end technology platforms focused on precision and functional validation.

Service Process

The Creative Biolabs CellRapeutics™ workflow is a rigorous, phased process designed for maximum control and customization, ensuring a clinical-grade engineered product ready for preclinical testing.

Seek consultation today to receive detailed specs and personalize your service bundle.

Related Services

The Highlight of Our CellRapeutics™ pan-ErbB-targeted Combination CAR-T cell Engineering Service

Q1: What are the safety & challenges considerations for ErbB-targeted CARs?

A1: Several criteria need to be taken into account:

• The persistence and migration of CAR-T cells to tumor sites for all ErbB-targeted CARs.
• The risk of on-target, off-tumor toxicity owing to the recognition of the ErbB family on normal tissue.
• The cytokine release syndrome (CRS) serves as a common side effect of CAR-T immunotherapy and is associated with an increase in inflammatory cytokines, such as IFN-γ and IL6.

Work with Creative Biolabs

Fig.3 Work with Creative Biolabs.

If you are interested in our CellRapeutics™ pan-ErbB-targeted combination CAR-T cell engineering service, please don't hesitate to contact us. Our experienced scientists try our best to meet the most challenging requirements and deliver the best answer for global customer satisfaction.

Reference

1. Boccalatte, F.; et al. Advances and Hurdles in CAR-T Cell Immune Therapy for Solid Tumors. Cancers. 2022; 14(20):5108.